See more : Triboo S.p.A. (TB.MI) Income Statement Analysis – Financial Results
Complete financial analysis of Sierra Oncology, Inc. (SRRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sierra Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Galaxy Entertainment Group Limited (0027.HK) Income Statement Analysis – Financial Results
- Etn. Fr. Colruyt NV (CUYTY) Income Statement Analysis – Financial Results
- Doro AB (publ) (DORO.ST) Income Statement Analysis – Financial Results
- BlackRock Latin American Investment Trust plc (BRLA.L) Income Statement Analysis – Financial Results
- Neogen Chemicals Limited (NEOGEN.BO) Income Statement Analysis – Financial Results
Sierra Oncology, Inc. (SRRA)
About Sierra Oncology, Inc.
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 67.15M | 45.12M | 53.25M | 41.08M | 30.16M | 33.90M | 26.36M | 19.08M | 2.84M |
| General & Administrative | 27.44M | 20.12M | 13.74M | 14.34M | 12.46M | 14.18M | 9.47M | 3.50M | 1.16M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.44M | 20.12M | 13.74M | 14.34M | 12.46M | 14.18M | 9.47M | 3.50M | 1.16M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 94.59M | 65.24M | 66.99M | 55.42M | 42.62M | 48.08M | 35.83M | 22.58M | 4.01M |
| Cost & Expenses | 94.59M | 65.24M | 66.99M | 55.42M | 42.62M | 48.08M | 35.83M | 22.58M | 4.01M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.72M |
| Depreciation & Amortization | 305.00K | 238.00K | 83.00K | 111.00K | 258.00K | 197.00K | 111.00K | 12.00K | 1.00K |
| EBITDA | -94.36M | -80.52M | -88.35M | -53.53M | -41.60M | -47.53M | -53.09M | -23.86M | -4.11M |
| EBITDA Ratio | 0.00% | -26,840.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -94.66M | -64.94M | -66.99M | -55.42M | -42.62M | -48.08M | -35.83M | -22.58M | -4.01M |
| Operating Income Ratio | 0.00% | -21,647.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | -15.82M | -21.44M | 1.78M | 760.00K | 351.00K | -17.38M | -1.29M | -2.83M |
| Income Before Tax | -94.66M | -80.76M | -88.44M | -53.64M | -41.86M | -47.72M | -53.21M | -23.87M | -6.83M |
| Income Before Tax Ratio | 0.00% | -26,920.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -3.00K | 142.00K | -160.00K | -302.00K | 156.00K | 143.00K | 55.00K | 2.00K | -108.00K |
| Net Income | -94.66M | -80.90M | -88.28M | -53.34M | -42.02M | -47.87M | -53.26M | -23.87M | -6.83M |
| Net Income Ratio | 0.00% | -26,967.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -7.14 | -7.70 | -30.30 | -30.16 | -33.68 | -63.32 | -147.95 | -56.76 | -13.19 |
| EPS Diluted | -7.14 | -7.70 | -30.30 | -30.16 | -33.68 | -63.32 | -147.95 | -56.76 | -13.19 |
| Weighted Avg Shares Out | 13.25M | 10.51M | 2.91M | 1.77M | 1.25M | 756.01K | 359.99K | 420.57K | 518.10K |
| Weighted Avg Shares Out (Dil) | 13.25M | 10.51M | 2.91M | 1.77M | 1.25M | 756.01K | 359.99K | 420.57K | 518.10K |
Sierra Oncology surges 50%, here is the catalyst
Sierra Oncology Inc. (NASDAQ: SRRA) shares are up 50% after the company announced a term loan deal with Oxford Finance LLC and the release of positive topline results from the vital Phase III MOMENTUM study. The MOMENTUM study, a global...
Sierra Oncology Secures Debt Facility Of Up To $125M With Oxford Finance To Support Momelotinib Development
Sierra Oncology Inc (NASDAQ: SRRA) has entered into a term loan agreement with Oxford Finance LLC to support the commercial preparation and potential launch of momelotinib. The Company estimates it held cash & cash equivalents of $104.7 million as of December 31, 2021.
Why Sierra Oncology Stock Is On Fire Today
Sierra's long-shot blood cancer drug scores a big win in a pivotal-stage trial.
Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis
SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced positive topline data from the pivotal Phase 3 MOMENTUM study—a global, randomized, double-blind clinical trial evaluating momelotinib (MMB)...
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted stock options to five new employees as approved by the Compensation Committee of the Company's...
Sierra Oncology Bets $216M On AstraZeneca's BET Inhibitor For Myelofibrosis
Sierra Oncology Inc (NASDAQ: SRRA) has acquired an exclusive global license from AstraZeneca Plc (NASDAQ: AZN) for AZD5153, a potent, and selective BRD4 BET inhibitor with a novel bivalent binding mode. Sierra plans to initiate a Phase 2 study evaluating momelotinib in combination with AZD5153...
Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline
SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced it has acquired an exclusive global license from AstraZeneca (LSE/STO/NASDAQ: AZN) for AZD5153,...
Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline
SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced it has acquired an exclusive global license from AstraZeneca (LSE/STO/NASDAQ: AZN) for AZD5153,...
Sierra Oncology Announces Completion of Enrollment for MOMENTUM Phase 3 Trial
—Topline data anticipated in Q1 2022 with NDA filing to follow in H2 2022— SAN MATEO, Calif., June 21, 2021 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat...
Sierra Oncology: Time To Enter For The Big Pie
For all practical purposes, Sierra Oncology today is a single product company, solely focused on its most advanced product, momelotinib, which is targeted at Myelofibrosis. There will likely be easier times ahead, which will allow investors to take calls on...
Source: https://incomestatements.info
Category: Stock Reports